ImageneBio

The firm operates on the premise that visualizing a drug's target engagement via PET imaging before committing to large efficacy trials reduces the probability of late-stage clinical failure. By developing a companion imaging agent alongside every therapeutic candidate, ImageneBio generates in-human pharmacokinetic and pharmacodynamic data early, allowing it to kill programs that fail to saturate their intended target. The approach draws from radiochemistry and nuclear medicine principles that have been validated in academic settings but rarely institutionalized as a mandatory portfolio-wide gating mechanism in biotech venture creation.

ImageneBio functions as an internal biotech incubator rather than a traditional fund that invests in external startups. The firm identifies underserved oncology targets, acquires or in-licenses targeting vectors with strong imaging potential, and then builds a subsidiary or internal program around each asset. This capital-efficient structure avoids the high overhead of a permanent corporate footprint, instead spinning up and down project-specific operational infrastructure as programs meet — or fail — their imaging-driven milestones.

The firm concentrates on oncology, with a particular emphasis on immuno-oncology targets such as CD8 T-cells and other tumor microenvironment biomarkers that can be labeled and tracked via PET. Its pipeline has historically included agents designed to image immune cell trafficking in solid tumors, leveraging the rationale that a visible T-cell infiltrate correlates with checkpoint inhibitor responsiveness. Some earlier-stage work also explored immuno-inflammatory indications outside oncology, though the restructured pipeline from late 2022 appears focused on two specific undisclosed cancer antigens.

James Gerson and Geoffrey Block co-founded the firm in 2018. Gerson brings a venture background from Oxeon Partners and MRL Ventures Fund, where he evaluated early-stage life-science opportunities, while Block is a trained radiochemist and researcher who shaped the technical architecture requiring imaging surrogate endpoints. Their combined expertise bridges biotech dealmaking and the specialized radiopharmaceutical development necessary to execute the imaging-first thesis consistently across a portfolio.

It is neither in the conventional sense. ImageneBio most closely resembles a biotech venture studio that creates and holds individual pipeline programs rather than managing a fund of third-party LP commitments. The firm does not publicly raise discrete venture funds or accept outside limited partners in a pooled structure, instead advancing programs through a centralized New York-based entity with a streamlined governance model that prioritizes imaging milestone attainment over institutional fundraising cycles.

Before a therapeutic enters a traditional Phase I dose-escalation study, the firm runs a microdosing PET imaging trial in a small patient cohort to confirm biodistribution and target saturation. This imaging pharmacokinetic data replaces assumptions that typically go untested until Phase II, reducing the likelihood that an otherwise promising molecule advances despite failing to engage its target in a living human. Trials are designed around this earlier data gate, often compressing timelines compared to conventional biotech pathways where clinical proof-of-mechanism is deferred.

ImageneBio has operated quietly since its 2018 founding without public announcements of large pharmaceutical partnerships or co-development deals on its platform programs. The firm's model is self-contained: it licenses in targeting vectors from academic institutions or other biotechs, develops the paired imaging and therapeutic agents internally, and appears to retain full ownership until a future out-licensing or acquisition event. No major disclosed collaborations with external GPs or pharma partners exist as of the most recent available record.